Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Sameditsino Parazitolog… | Healthcare Services | 15.7% | 67th pct | 268 |
| Tvalis Klinika | Healthcare Services | 11.2% | 55th pct | 268 |
| Saprotezo Ortopediuli R… | Healthcare Services | 9.3% | 49th pct | 268 |
| Atlas Medical | Healthcare Services | — | no FY data | 268 |
| Med-Diagnostika | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Tvalis Klinika | Sameditsino Parazitolog… | Saprotezo Ortopediuli R… | Atlas Medical | Med-Diagnostika |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 100.0% | 54.3% | 64.1% | — | — |
| EBITDA Margin | 11.2% | 15.7% | 9.3% | — | — |
| EBITDAR | 180 | 195 | 82 | — | — |
| EBITDAR Margin | 14.3% | 15.7% | 9.3% | — | — |
| EBIT Margin | 6.4% | 14.9% | 4.9% | — | — |
| Net Profit Margin | -11.2% | 19.2% | 5.5% | — | — |
| Operating Expense % of Sales | 88.8% | 38.5% | 54.7% | — | — |
| Returns | |||||
| Return on Assets (ROA) | -2.9% | 18.8% | 3.5% | — | — |
| Return on Equity (ROE) | -29.5% | 21.6% | 5.4% | — | — |
| ROIC [EBIT / Invested Capital] | 2.0% | 102.2% | 3.3% | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 82.2% | 10.1% | 33.9% | — | — |
| Debt-to-Equity | 8.34x | 0.12x | 0.53x | — | — |
| Debt-to-EBITDA | 28.28x | 0.66x | 5.74x | — | — |
| Equity-to-Assets | 9.9% | 87.0% | 64.5% | — | — |
| Net Debt | 3,551 | -922 | 400 | — | — |
| Cash & Equivalents | 446 | 1,050 | 68 | — | — |
| Total Debt | 3,996 | 128 | 468 | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.11x | 32.21x | 7.16x | — | — |
| Quick Ratio | 1.11x | 32.21x | 7.16x | — | — |
| Cash Ratio | 0.52x | 29.04x | 3.08x | — | — |
| Total Current Assets | 941 | 1,165 | 157 | — | — |
| Total Current Liabilities | 849 | 36 | 22 | — | — |
| Inventory | N/A | N/A | N/A | — | — |
| Trade Receivables | 433 | 80 | 90 | — | — |
| Trade Payables | 330 | 31 | 22 | — | — |
| Net Working Capital | 92 | 1,129 | 135 | — | — |
| Net Working Capital % of Revenue | 7.3% | 90.9% | 15.5% | — | — |
| Trade Working Capital | 102 | 48 | 68 | — | — |
| Trade Working Capital % of Revenue | 8.1% | 3.9% | 7.7% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | — | — |
| Receivables Turnover | 2.91x | 15.61x | 9.75x | — | — |
| Days Sales Outstanding (DSO) | 125.3 | 23.4 | 37.4 | — | — |
| Payables Turnover | N/A | 18.11x | 14.28x | — | — |
| Days Payable Outstanding (DPO) | N/A | 20.2 | 25.6 | — | — |
| Cash Conversion Cycle | 125.3 days | 3.2 days | 11.9 days | — | — |
| Asset Turnover | 0.26x | 0.98x | 0.63x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | -67 | N/A | N/A | — | — |
| Free Cash Flow (OCF − Capex proxy) | -67 | N/A | N/A | — | — |
| Cash Conversion (OCF / EBITDA) | -47.5% | N/A | N/A | — | — |
| Dividends Declared | N/A | N/A | N/A | — | — |
| Dividend Payout Ratio | N/A | N/A | N/A | — | — |